CRP Specific Neutra™ Antibody Products
Product listAccelerate Your Research and Development!
Are you currently facing challenges in accurately quantifying C-Reactive Protein (CRP) in high-sensitivity clinical assays or struggling with antibody specificity for both pentameric (pCRP) and monomeric (mCRP) forms? Our CRP Specific Neutra™ Antibody Products help you achieve ultra-sensitive and reliable CRP detection, enabling robust inflammatory disease diagnostics and research through innovative high-specificity antibody engineering techniques.
Contact our team to get an inquiry now!
Introduction of CRP
C-Reactive Protein (CRP) is a major acute-phase reactant, serving as a rapid, non-specific biomarker of inflammation and tissue damage. Structurally, CRP is a member of the pentraxin family, comprising five identical, non-covalently linked subunits that form a stable, annular, pentameric structure (pCRP), which is crucial for its biological function. Synthesized primarily by hepatocytes in the liver, CRP production swiftly increases in response to pro-inflammatory cytokines, especially Interleukin-6 (IL-6). Its core function in innate immunity is to recognize and bind phosphocholine on foreign pathogens and damaged cell membranes. Upon binding, pCRP acts as an opsonin to promote phagocytosis and, critically, activates the classical complement pathway by binding to C1q. Clinically, elevated CRP levels monitor inflammatory, infectious, and tissue-destructive conditions. Furthermore, high-sensitivity assays (hs-CRP) show that persistently low-level CRP is a significant, independent risk factor for cardiovascular events, reflecting underlying vascular inflammation and atherosclerosis.
Fig.1 The native structure and associated activities of CRP.1
Antibodies Against CRP
Antibodies targeting CRP are essential for both clinical diagnostics and fundamental immunological research, primarily to quantify the protein across its concentration range—from high levels during acute infection to minute quantities in chronic, low-grade inflammation (hs-CRP).
- In diagnostics, highly specific, high-affinity monoclonal antibodies are the foundation for quantitative immunoassays (e.g., turbidimetric, nephelometric, and standard ELISA) used globally. Their specificity is vital to prevent cross-reactivity with other acute-phase proteins.
- For research, anti-CRP antibodies are crucial for differentiating between the circulating pentameric form (pCRP) and the biologically distinct monomeric form (mCRP). Found at inflammation sites, mCRP exposes neoepitopes and exhibits distinct pro-inflammatory activities. Researchers require highly specific antibodies to selectively detect these neoepitopes, enabling the study of mCRP's role in inflammation and repair. Creative Biolabs' Neutra™ antibodies are engineered precisely to meet this specificity challenge for all critical CRP research and diagnostic applications.
Why Choose Us?
Choosing Creative Biolabs means partnering with a specialist committed to scientific precision, robust product performance, and over 20 years of biopharmaceutical research support. Our Neutra™ product line is specifically designed for the rigorous demands of diagnostic developers and immunology researchers.
Key Advantages of the Creative Biolabs Neutra™ Antibody Platform:
- Ultra-High Specificity: Proprietary screening ensures minimal cross-reactivity, delivering unparalleled specificity vital for hs-CRP detection and differential recognition of pCRP and mCRP.
- Unmatched Lot-to-Lot Consistency: Stringent manufacturing and QC protocols guarantee excellent reproducibility, essential for long-term assay development and regulatory approval.
- Validated for Diverse Applications: Each product is extensively validated across multiple platforms (ELISA, WB, IHC), providing confidence in performance across any application workflow.
FAQs
Q: What is the primary factor influencing the selection of a capture antibody versus a detection antibody for a high-sensitivity C-Reactive Protein (hs-CRP) sandwich assay?
A: The most critical factor is the epitope-binding site: both antibodies must target spatially distinct, non-overlapping regions (epitopes) of the CRP molecule. For hs-CRP assays, high affinity and specificity for CRP's stable structure are essential to ensure maximum signal output and a very low limit of detection (nanogram/milliliter range).
Q: How does the purity of the antibody preparation affect the performance of a quantitative diagnostic test for inflammatory biomarkers?
A: High purity is crucial because contaminants (such as host cell proteins or fragments) increase background noise and non-specific binding, directly compromising sensitivity and specificity. Highly purified antibodies ensure the signal accurately reflects the target concentration, yielding a cleaner signal and more reliable quantification.
Q: When studying inflammation, how can I ensure my antibody is detecting the biologically active form of CRP rather than inactive aggregates?
A: Select antibodies validated specifically against the native pentameric structure (pCRP) or, for localized activity, against the neo-epitopes exposed on the monomeric form (mCRP). Validation should include confirmation via non-reducing Western Blot and comparison with validated pCRP/mCRP standards.
Q: Are there any specific storage or handling precautions recommended for anti-biomarker antibodies to maintain their long-term functionality?
A: Yes, proper storage is vital. For long-term use, aliquot the stock to avoid repeated freeze-thaw cycles, storing typically at −20 ℃ or −80 ℃. Working stock should be kept at 4 ℃ for short periods, ideally with a carrier protein added for stability.
Q: How do immunoassay-based methods compare to traditional clinical chemistry methods (like immunoturbidimetry) in terms of utility for large-scale CRP research studies?
A: While immunoturbidimetry is the clinical standard for high-volume measurements, plate-based immunoassays (like ELISA) offer greater flexibility for research. They allow for higher throughput, require less sample volume, and are easily customized (e.g., using pCRP/mCRP differentiating pairs), providing deeper mechanistic insight than standard clinical quantification.
Access the Creative Biolabs Edge – Request Your Quote Now
REFERENCE
- Zhou, Hai-Hong et al. "C-reactive protein: structure, function, regulation, and role in clinical diseases." Frontiers in immunology vol. 15 1425168. 14 Jun. 2024, Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3389/fimmu.2024.1425168
